Nasdaq
$10.02▲ 2.14%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $284.8MShares out 28.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.7Pre-market26.10.07 20:17SCHEDULE 13G/AOwnership#●●●
Arcturus Therapeutics Holdings Inc.
Federated Hermes, Inc., its affiliates, and associated trustees have filed a joint Schedule 13G regarding their holdings in Arcturus Therapeutics Holdings Inc. The reporting persons clarify that while they exercise voting power over shares held by funds and accounts under their advisory, they expressly disclaim beneficial ownership of the reported securities.…more
$10.02+2.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.23After-hours26.09.24 05:118-KKey event
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810 and introduced its next-generation mRNA delivery platform, LUNAR 2.0. The company plans to integrate ARCT-2601, which utilizes LUNAR 2.0, into its ongoing Phase 2 study by the end of 2026 and has entered into a definitive agreement to acquire the AI company myNEO.…more
$10.02+2.14%vs prev closeView filingShare - 8.25Pre-market26.08.25 19:008-KKey event
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics is presenting data on the impact of its ARCT-810 mRNA therapy on patients with Ornithine Transcarbamylase Deficiency at the 2026 Annual Symposium in Helsinki on August 25, 2026. Additional clinical data and the regulatory plan for this program are expected to be communicated later this quarter.…more
$10.02+2.14%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.24Regular26.09.25 03:26#●●●#●●●#●●●
Arcturus Therapeutics Rises on Positive Phase 2 Data and New Platform Launch…more
Arcturus Therapeutics announced positive interim Phase 2 trial results for its OTC deficiency treatment, ARCT-810, and unveiled its next-generation mRNA delivery platform. The company also signed an agreement to acquire myNEO to strengthen its AI infrastructure and technological capabilities.…more
$10.02+2.14%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23After-hours26.09.24 05:04
●●●●●●●● ●●●●● ●●●●●●
Arcturus has entered into a definitive agreement to acquire myNEO to enhance its mRNA design and target identification capabilities. The financial terms of the deal were not disclosed, and the transaction is expected to close in October.…more
$10.02+2.14%vs prev closeShareBenzinga - 9.23After-hours26.09.24 05:02
●●●●●●●● ●●●●● ●●●●●●
Arcturus Therapeutics reported encouraging interim Phase 2 data for its OTC deficiency candidate, ARCT-810. The company also announced the acquisition of AI-driven discovery firm myNEO to enhance its mRNA design capabilities and LUNAR 2.0 platform.…more
$10.02+2.14%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report